Biological, molecular, and clinical markers for the diagnosis and typing of lung cancer

Adi F. Gazdar, James L. Mulshine, Barnett S. Kramer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Lung cancer is the most common form of cancer as well as the leading cause of cancer deaths in the United States. Approximately 90% of patients eventually die from their disease [1]. Newer forms of therapy are therefore needed. In addition, improvements in our current diagnostic, staging, and typing methodologies would be of benefit. Lung cancer presents a pradoxical situation for the biologist and clinician. While numerous excellent biological and molecular markers are available for tumor tissue diagnosis, typing, and progression, few, if any, have successfully weathered the perilous journey from laboratory to bedside. In this chapter we will discuss the reasons for this paradox, and critically assess the more promising of the many markers clinicians have attempted to use in the management of this disease.

Original languageEnglish (US)
Title of host publicationImmunodiagnosis of Cancer
Subtitle of host publicationSecond Edition
PublisherCRC Press
Pages453-468
Number of pages16
ISBN (Electronic)9781351439251
ISBN (Print)9780824782993
DOIs
StatePublished - Jan 1 2017

Fingerprint

Tumor Biomarkers
Tissue

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Gazdar, A. F., Mulshine, J. L., & Kramer, B. S. (2017). Biological, molecular, and clinical markers for the diagnosis and typing of lung cancer. In Immunodiagnosis of Cancer: Second Edition (pp. 453-468). CRC Press. https://doi.org/10.1201/9780203751268

Biological, molecular, and clinical markers for the diagnosis and typing of lung cancer. / Gazdar, Adi F.; Mulshine, James L.; Kramer, Barnett S.

Immunodiagnosis of Cancer: Second Edition. CRC Press, 2017. p. 453-468.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gazdar, AF, Mulshine, JL & Kramer, BS 2017, Biological, molecular, and clinical markers for the diagnosis and typing of lung cancer. in Immunodiagnosis of Cancer: Second Edition. CRC Press, pp. 453-468. https://doi.org/10.1201/9780203751268
Gazdar AF, Mulshine JL, Kramer BS. Biological, molecular, and clinical markers for the diagnosis and typing of lung cancer. In Immunodiagnosis of Cancer: Second Edition. CRC Press. 2017. p. 453-468 https://doi.org/10.1201/9780203751268
Gazdar, Adi F. ; Mulshine, James L. ; Kramer, Barnett S. / Biological, molecular, and clinical markers for the diagnosis and typing of lung cancer. Immunodiagnosis of Cancer: Second Edition. CRC Press, 2017. pp. 453-468
@inbook{c9c44a6c031245fd84ee3ea87275392d,
title = "Biological, molecular, and clinical markers for the diagnosis and typing of lung cancer",
abstract = "Lung cancer is the most common form of cancer as well as the leading cause of cancer deaths in the United States. Approximately 90{\%} of patients eventually die from their disease [1]. Newer forms of therapy are therefore needed. In addition, improvements in our current diagnostic, staging, and typing methodologies would be of benefit. Lung cancer presents a pradoxical situation for the biologist and clinician. While numerous excellent biological and molecular markers are available for tumor tissue diagnosis, typing, and progression, few, if any, have successfully weathered the perilous journey from laboratory to bedside. In this chapter we will discuss the reasons for this paradox, and critically assess the more promising of the many markers clinicians have attempted to use in the management of this disease.",
author = "Gazdar, {Adi F.} and Mulshine, {James L.} and Kramer, {Barnett S.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1201/9780203751268",
language = "English (US)",
isbn = "9780824782993",
pages = "453--468",
booktitle = "Immunodiagnosis of Cancer",
publisher = "CRC Press",

}

TY - CHAP

T1 - Biological, molecular, and clinical markers for the diagnosis and typing of lung cancer

AU - Gazdar, Adi F.

AU - Mulshine, James L.

AU - Kramer, Barnett S.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Lung cancer is the most common form of cancer as well as the leading cause of cancer deaths in the United States. Approximately 90% of patients eventually die from their disease [1]. Newer forms of therapy are therefore needed. In addition, improvements in our current diagnostic, staging, and typing methodologies would be of benefit. Lung cancer presents a pradoxical situation for the biologist and clinician. While numerous excellent biological and molecular markers are available for tumor tissue diagnosis, typing, and progression, few, if any, have successfully weathered the perilous journey from laboratory to bedside. In this chapter we will discuss the reasons for this paradox, and critically assess the more promising of the many markers clinicians have attempted to use in the management of this disease.

AB - Lung cancer is the most common form of cancer as well as the leading cause of cancer deaths in the United States. Approximately 90% of patients eventually die from their disease [1]. Newer forms of therapy are therefore needed. In addition, improvements in our current diagnostic, staging, and typing methodologies would be of benefit. Lung cancer presents a pradoxical situation for the biologist and clinician. While numerous excellent biological and molecular markers are available for tumor tissue diagnosis, typing, and progression, few, if any, have successfully weathered the perilous journey from laboratory to bedside. In this chapter we will discuss the reasons for this paradox, and critically assess the more promising of the many markers clinicians have attempted to use in the management of this disease.

UR - http://www.scopus.com/inward/record.url?scp=85051314382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051314382&partnerID=8YFLogxK

U2 - 10.1201/9780203751268

DO - 10.1201/9780203751268

M3 - Chapter

AN - SCOPUS:85051314382

SN - 9780824782993

SP - 453

EP - 468

BT - Immunodiagnosis of Cancer

PB - CRC Press

ER -